The first studies bring good news about the Russian vaccine against coronavirus

“The measures taken here are strict but they have managed to alleviate the pandemic”

Seven and a half months after they were repatriated, eight of the Wuhan Three Towns FC's Spanish workers they have returned to china. ...

An American professor living in Finland praises Finland to the LA-Times: “Who would go back?”

American Professor Emeritus David Kirp has lived in Finland together with her Finnish spouse since the beginning of April.In six months, Kirp has noticed...

A judge prevents the Trump administration from vetoing TikTok in the United States

The precautionary decision comes hours before the application was forced to disappear from digital stores by order of the White HouseA federal judge in...

Judge prevents ban of TikTok in the US at least temporarily

A United States judge issued an order this Sunday that prevents the Government of Donald Trump from banning downloads and updates from the...

Confrontation between armed groups in Colombia leaves six dead

Colombian authorities confirmed this Sunday that at least six people died in a confrontation between two illegal armed groups in an indigenous reservation...

According to the first tests, it managed to generate antibodies and did not cause serious adverse effects. But more in-depth clinical trials are still lacking, according to The Lancet.

A preliminary study on the vaccine that Russia is developing against the coronavirus showed that it develops an immune response without serious undesirable effects, according to the prestigious specialized magazine published on Friday. The Lancet. But larger work is still needed to determine its eventual effectiveness.

The study, conducted by Russian government researchers, was evaluated by a rereading committee of the British medical journal prior to publication.

The Russian authorities announced last month that their vaccine, called Sputnik V, was entering the third and final phase of clinical trials, but that they were not going to wait for the results of this since they intended to homologate it in September.

The announcement was met with skepticism by many researchers and countries such as Germany and the United States, which questioned its efficacy and safety, mainly due to the absence of public data on the trials conducted so far.

The World Health Organization (WHO) for its part called on Russia to follow the established protocol and comply with “all the phases” necessary to develop a safe vaccine.

The WHO “will not endorse” a coronavirus vaccine if it is not safe and effective, its director general, Tedros Adhanom Ghebreyesus, declared on Friday.

Moscow has denounced these criticisms as an attempt to dismiss the Russian investigation.

President Vladimir Putin went further and claimed that the vaccine, developed by the government and the Gamaleïa Research Institute, guaranteed “lasting immunity” to COVID-19.

Sputnik V actually consists of two vaccines, administered in injections each three weeks apart, the study published in The Lancet detailed.

It is a “viral vector” vaccine: it uses two human adenoviruses – a very common family of viruses, mainly responsible for colds -, which are transformed to add the SARS-CoV-2 virus, which causes covid-19.

When the modified adenovirus enters the cells of the vaccinated person, it manufactures a typical SARS-CoV-2 protein, thus teaching their immune system to recognize and fight it, explains the lead author of the article, Denis Logounov, from the Gamaleïa Institute.

The publication is based on two small studies conducted among a total of 76 adult volunteers, between 18 and 60 years old, in good health. They were carried out between June 18 and August 3 by researchers from the Russian ministries of Health and Defense and funded by the former.

Both concluded that neither of the two components of the vaccine caused “serious undesirable effects” and that its successive administration “generated the production of antibodies” in all participants, including “neutralizing antibodies” to covid-19.

Now “large trials are needed, with a longer follow-up and including comparison with a placebo” to “establish the safety over time and the efficacy of the vaccine in preventing infection with COVID-19,” the authors stated. .

This will be the goal of the phase 3 trial, which will include 40,000 participants, “of various ages and with different risk levels,” they explained.

These results are “encouraging, but on a small scale” and they do not clarify whether the vaccine provokes an immune response among the elderly, the most vulnerable to the coronavirus, reacted Naor Bar-Zeev, a vaccine specialist at the Johns Hopkins Bloomberg School of Public Health, in the United States.


Related Articles